Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | RET | P07949 | 12/20 | 0.56 |
| ▸ | KDR | P35968 | 8/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12422349 | 0.88 | PIK3CD (0.84) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL12422388 | 0.86 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL12422360 | 0.85 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL12422402 | 0.85 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL12422380 | 0.84 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL1551638 | 0.83 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL21082439 | 0.82 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL1297293 | 0.81 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL17461932 | 0.79 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3CARETKDR | |
| SCHEMBL21082753 | 0.78 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3CARETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013078440-A2 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013070976-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | PIK3CD 6/4885PIK3CG 11/4885PIK3CA 1/4885 |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | RICTOR, MTOR, RPTOR | PIK3CD 58/4885PIK3CG 141/4885PIK3CA 21/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | PIK3CD 150/4885PIK3CG 282/4885PIK3CA 132/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | PIK3CD 446/4885PIK3CG 758/4885PIK3CA 363/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | PIK3CD 2330/4885PIK3CG 2918/4885PIK3CA 1540/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PIK3CD 24/4885PIK3CG 50/4885PIK3CA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.